Fuster Oscar, Barragán Eva, Bolufer Pascual, Cervera José, Larráyoz Maria José, Jiménez-Velasco Antonio, Martínez-López Joaquín, Valencia Ana, Moscardó Federico, Sanz Miguel Angel
Laboratory of Molecular Biology, Department of Medical Pathology, Escuela de enfermería 7 planta. Hospital Universitario La Fe, Avd. Campanar 21, Valencia 46009, Spain.
J Mol Diagn. 2009 Sep;11(5):458-63. doi: 10.2353/jmoldx.2009.090043. Epub 2009 Jul 30.
The most frequent KIT mutations reported in core-binding factor acute myeloid leukemia are point mutations and insertions/deletions in exons 17 and 8. The vast majority of KIT mutation detection procedures are time-consuming, costly, or with a high lower limit of detection. High-resolution melting (HRM) is a gene scanning method that combines simplicity and rapid identification of genetic variants. We describe an HRM method for the simultaneous screening of exons 8 and 17 KIT mutations and report the results obtained in 69 core-binding factor acute myeloid leukemia patients. Mutation detection was compared with sequencing as the gold standard. The HRM method used high-resolution melting master reagents (Roche) and the LightCycler 480 (Roche) platform. HRM was reproducible, showed a lower limit of detection of 1%, and discriminated all patients with mutated KIT from controls without false positive or false negative results. Additionally, most of the mutations were differentiated from the other mutations. KIT mutations were present in 15.9% of patients, showing a higher incidence in inv(16) (25.8%) than in t(8;21) (7.9%). The presence of a KIT mutation was associated with a high white blood cell count, and adult patients with an exon 17 mutation had a higher incidence of relapse. These findings verify that HRM is a reliable, rapid, and sensitive method for KIT mutation screening. Furthermore, our study corroborates the unfavorable prognosis associated with exon 17 KIT mutations.
在核心结合因子急性髓系白血病中报告的最常见的KIT突变是外显子17和8中的点突变以及插入/缺失。绝大多数KIT突变检测程序耗时、成本高或检测下限高。高分辨率熔解(HRM)是一种结合了简单性和快速识别基因变异的基因扫描方法。我们描述了一种用于同时筛查KIT基因外显子8和17突变的HRM方法,并报告了在69例核心结合因子急性髓系白血病患者中获得的结果。将突变检测与作为金标准的测序进行了比较。HRM方法使用高分辨率熔解主试剂(罗氏)和LightCycler 480(罗氏)平台。HRM具有可重复性,检测下限为1%,能将所有KIT突变患者与对照组区分开来,无假阳性或假阴性结果。此外,大多数突变与其他突变相区分。15.9%的患者存在KIT突变,inv(16)患者中的发生率(25.8%)高于t(